Johnson & Johnson

Johnson & Johnson will complete its $19.7 billion purchase of Synthes Thursday, more than 13 months after it agreed to buy the Swiss orthopedic device maker.

Read More|Comment

A majority of Food and Drug Administration panelists have voted against a new use for Johnson & Johnson's blood thinner Xarelto to reduce life-threatening blood clots.

Read More|Comment

Johnson & Johnson shareholders, upset over the health giant's battered image amid unprecedented product recalls and ethical lapses, peppered its new CEO with questions and criticism during J&J's annual meeting.

Read More|Comment

Johnson & Johnson's incoming CEO plans to present himself as a "realistic optimist" when he addresses shareholders at the health care giant's annual meeting Thursday.

Read More|Comment

An Arkansas judge has fined Johnson & Johnson and a subsidiary more than $1.1 billion after a jury found the companies downplayed and hid risks associated with an antipsychotic drug.

Read More|Comment

Jurors have ruled against a Johnson & Johnson subsidiary in Arkansas' billion-dollar lawsuit over the antipsychotic drug Risperdal.

Read More|Comment

Johnson & Johnson says it is bumping up the bonus of retiring CEO Bill Weldon by 55 percent in 2012.

Read More|Comment

Johnson & Johnson's longtime CEO, Bill Weldon, is retiring this April, following an embarrassing string of product recalls that has stretched for more than 2 years, costing the health care giant hundreds of millions of dollars and consumer trust.

Read More|Comment

Two executives in Johnson & Johnson's recall-riddled consumer products business are departing in two months.

Read More|Comment

A person familiar with negotiations tells The Associated Press that Johnson & Johnson and the state of Texas have reached a settlement in a lawsuit in which the state was seeking up to $1 billion from the New Jersey based drug maker.

Read More|Comment